Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulsatile Intravenous FSH for Reprometabolic Syndrome
NCT06414096Phase 1Recruiting
- Sponsor
- University of Colorado Denver
- Start
- Oct 2024
- Primary completion
- Nov 2031
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of follitropin in infertility and Diminished Ovarian Reserve (DOR) (2 arms), sponsored by University of Colorado Denver. Primary endpoints: Urinary Pregnanediol Glucuronide concentration at 4 months and Number of oocytes retrieved at 4 months. Started Oct 2024; status: recruiting.
02
Drugs
follitropin
03
Conditions
infertilityDiminished Ovarian Reserve (DOR)
Beyond the preview
Go deeper on NCT06414096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06414096.